These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32802709)

  • 1. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
    Terawaki Y; Iwaya C; Nomiyama T; Shimono D; Horikawa T; Fujimura-Tanaka Y; Shigeoka T; Hamanoue N; Motonaga R; Tanabe M; Yanase T; Kawanami D;
    Diabetol Int; 2020 Jul; 11(3):274-282. PubMed ID: 32802709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
    Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
    Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.
    Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W
    Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
    Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
    Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan.
    Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Sep; 7(3):299-307. PubMed ID: 30603277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
    Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
    Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Kaku K; Hanafusa T; Kashiwabara D; Kageyama S; Hotta N
    J Diabetes Investig; 2012 Jun; 3(3):302-8. PubMed ID: 24843581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers.
    Yamazaki M; Hasegawa G; Majima S; Mitsuhashi K; Fukuda T; Iwase H; Kadono M; Asano M; Senmaru T; Tanaka M; Fukui M; Nakamura N
    Diabetol Metab Syndr; 2014; 6():54. PubMed ID: 24843385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study.
    Okajima F; Sugihara H; Emoto N
    J Nippon Med Sch; 2021 Mar; 88(1):71-79. PubMed ID: 32475902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
    Ishihara H; Anai M; Seino H; Kitazawa T; Ohashi H; Ai M; Inoue M; Fujishiro M; Inazawa T; Kuroda H; Yamada M
    Diabetes Ther; 2018 Oct; 9(5):2117-2125. PubMed ID: 30145651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
    Mohan V; Ramu M; Poongothai S; Kasthuri S
    J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
    Park SH; Jeong HE; Oh IS; Hong SM; Yu SH; Lee CB; Shin JY
    Diabetes Obes Metab; 2021 Jun; 23(6):1232-1241. PubMed ID: 33502058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.
    Yoneda C; Kobayashi J; Kuribayashi N
    Diabetol Int; 2024 Jul; 15(3):569-576. PubMed ID: 39101186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.
    Ishii H; Ohkubo Y; Takei M; Nishio S; Yamazaki M; Kumagai M; Sato Y; Suzuki S; Aoki Y; Miyamoto T; Kakizawa T; Sakuma T; Komatsu M
    J Clin Med Res; 2014 Apr; 6(2):127-32. PubMed ID: 24578754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.